<DOC>
	<DOCNO>NCT02028364</DOCNO>
	<brief_summary>This prospective , single arm trial patient locally advance metastatic endocrine receptor positive HER2 negative breast cancer refractory non-steroidal aromatase inhibitor ( NSAI ) receive Everolimus 10mg orally daily give conjunction exemestane 25mg orally daily disease progression treatment discontinuation reason . Tumour , metastatic lesion blood sample collect treatment period . Genomic analysis metastatic tumour tissue specimens `` liquid biopsy '' help identify patient benefit treatment regimen . The main objective evaluate early metabolic response ( MR ) use FDG-PET/CT associated progression free survival ( PFS ) population .</brief_summary>
	<brief_title>Pet Imaging Biomarker Hormone Refractory postmenopausaL Women</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Adult woman ( ≥18 year age ) locally advanced metastatic breast cancer amenable curative treatment surgery radiotherapy . Histological cytological confirmation estrogenreceptor positive ( ER+ ) , HER2 negative breast cancer . Postmenopausal female define : Age ≥55 year one year amenorrhoea Age &lt; 55 year one year amenorrhoea , estradiol assay &lt; 20pg/ml Surgical menopause bilateral oophorectomy Breast cancer refractory nonsteroidal aromatase inhibitor ( NSAI ) ( i.e . anastrozole letrozole ) define : Recurrence , within 12 month end adjuvant treatment anastrozole letrozole ; OR Progression , within one month end anastrozole letrozole treatment locally advance metastatic breast cancer . FDGPET measurable disease define : least one target lesion fulfil follow criterion : Size ≥1.5cm ; AND FDGPET avid lesion uptake background liver uptake described : i.e . mark accumulation FDG , least 1.5fold great liver SUV mean + 2 SDs ( 3cm spherical ROI normal right lobe liver ) . If liver abnormal , target lesion uptake &gt; 2.0 x SUV mean blood pool 1cm diameter ROI descend thoracic aorta ) The patient must least 1 PETCT measurable lesion also measurable accord RECIST 1.1 criterion . Radiological clinical evidence recurrence progression last systemic therapy prior enrolment . Adequate bone marrow coagulation function show : Haemoglobin ( HgB ) ≥9.0 g/dL ANC ≥1,500/mm3 ( ≥1.5 x 109/L ) Platelets ≥100,000/mm3 ( ≥100x 109/L ) INR ≤2.0 Adequate liver function show : Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤2.5xULN ( ≤5 hepatic metastasis present ) Total serum bilirubin ≤1.5 x ULN ( ≤3 ULN patient know Gilbert Syndrome ) Adequate renal function show Serum creatinine ≤1.5 x ULN Fasting serum cholesterol , triglyceride glucose Fasting serum cholesterol ≤300 mg/dL 7.75 mmol/L Fasting triglycerides ≤2.5 x ULN Fasting glucose &lt; 1.5 x ULN Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 . Written sign inform consent obtain trial related activity . Availability FFPE core primary breast tumor Possibility obtain blood sample translational research study . For patient accessible metastatic lesion , possibility obtain biopsy ( FFPE frozen ) metastatic lesion Exclusion criterion : HER2overexpressing patient local laboratory testing ( IHC 3+ stain situ hybridization positive ) . Patients nonmeasurable lesion FDGPET ( e.g . pleural effusion , ascites etc. ) . Symptomatic visceral disease example liver , pulmonary metastasis lymphangitis carcinomatosis . Known hypersensitivity mTOR inhibitor , e.g . sirolimus ( rapamycin ) . Another malignancy within 5 year prior enrolment , exception adequately treat insitu carcinoma cervix , uteri , basal squamous cell carcinoma nonmelanomatous skin cancer . Radiotherapy within four week prior enrolment except case localize radiotherapy analgesic purpose lytic lesion risk fracture , complete within two week prior enrolment . Patients must recover radiotherapy toxicity prior enrolment . Currently receive hormone replacement therapy , unless discontinue prior enrolment . History symptomatic brain metastasis central nervous system metastasis . Patients receive concomitant immunosuppressive agent chronic corticosteroid use time study entry except case outline : Topical application ( e.g . rash ) Inhaled spray ( e.g . obstructive airway disease ) Eye drop Local injection ( e.g . intraarticular ) Stable low dose corticosteroid least two week enrolment Patients know HIV seropositivity . Screening HIV infection baseline require Acute chronic , active infectious disorder ( except Hepatitis B Hepatitis C positive patient ) . Active bleeding diathesis , oral antivitamin K medication ( except low dose warfarin , LMWH acetylsalicylic acid equivalent , long INR ≤ 2.0 ) . Any severe uncontrolled medical condition : Unstable angina pectoris , symptomatic congestive heart failure , myocardial infarction ≤6 month prior enrolment , uncontrolled cardiac arrhythmia Uncontrolled diabetes define fast glucose ≥ 1.5 x ULN Acute chronic , active infectious disorder nonmalignant medical illness uncontrolled whose control may jeopardize complication study therapy . Symptomatic deterioration lung function Patients treat drug recognize strong inhibitor inducer isoenzyme CYP3A ( Rifabutin , Rifampicin , Clarithromycin , Ketoconazole , Itraconazoleonazole , Voriconazole , Ritonavir , Telithromycin ) within last 5 day prior enrolment . History noncompliance medical regimen . Patients unwilling unable comply protocol . Concurrent anticancer treatment another investigational trial , include hormonal therapy , immunotherapy target agent administer study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Locally advanced breast cancer</keyword>
	<keyword>HER2 negative</keyword>
	<keyword>NSAI refractory</keyword>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>Estrogen-receptor positive ( ER+ )</keyword>
</DOC>